Your browser doesn't support javascript.
loading
The Finnish Diabetes Risk Score (FINDRISC), incident diabetes and low-grade inflammation.
Pesaro, Antonio E; Bittencourt, Márcio Sommer; Franken, Marcelo; Carvalho, Jose A M; Bernardes, Daniel; Tuomilehto, Jaakko; Santos, Raul D.
Afiliação
  • Pesaro AE; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil. Electronic address: antonioepp@einstein.br.
  • Bittencourt MS; Hospital Universitario, University of Sao Paulo Medical School, Sao Paulo, Brazil.
  • Franken M; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
  • Carvalho JAM; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
  • Bernardes D; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
  • Tuomilehto J; Finnish Institute for Health and Welfare, Helsinki, Finland; Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Santos RD; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil; Heart Institute (InCor) University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil.
Diabetes Res Clin Pract ; 171: 108558, 2021 Jan.
Article em En | MEDLINE | ID: mdl-33242513
ABSTRACT

AIMS:

The FINDRISC was created to predict the development of type 2 diabetes mellitus (T2DM). Since T2DM associates with inflammation we evaluated if the FINDRISC could predict either current or incident T2DM, and elevated high sensitivity C-reactive protein (hs-CRP).

METHODS:

41,880 people (age 41.9 ± 9.7 years; 31% female) evaluated between 2008 and 2016 were included. First, the cross-sectional association between the FINDRISC with presence of either T2DM or hs-CRP ≥ 2.0 mg/L was tested. After a 5 ± 3 years follow-up we tested the score predictive value for incident T2DM and inflammation in respectively 10,559 individuals without diabetes and in a subset of 2,816 individuals having no elevated hs-CRP at baseline.

RESULTS:

In the cross sectional analysis the FINDRISC was associated with both T2DM (OR 1.24, 95% CI 1.23-1.26, P < 0.001) and inflammation (OR 1.10, 95% CI 1.09-1.11, P < 0.001) per FINDRISC unit, as well as in longitudinal analyses (OR 1.17, 95% CI 1.14-1.20, P < 0.001; and OR 1.04, 95% CI 1.02-1.07, P < 0.001; respectively, per FINDRISC unit). The C-statistic for incident T2DM and inflammation was 0.79 (95% CI 0.77-0.82) and 0.55 (95% CI 0.53-0.58), respectively.

CONCLUSION:

The FINDRISC shows good discrimination for incident T2DM but less for inflammation.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Inflamação Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Inflamação Idioma: En Ano de publicação: 2021 Tipo de documento: Article